IPCA Labs presents a good opportunity for us to test the veracity of the hypothesis that you must buy when the uncertainty is high & risk is low. This theory worked wonders in MCX, Muthoot Finance, Ranbaxy etc and it looks likely to work wonders in IPCA Labs as well
David Nadel of Royce Intl. Small-Cap Fund has identified 7 top-quality mid-cap stocks with high ROE that he says are extremely cheap on valuations and with great scalability
Motilal Oswal and Microsec have issued independent research reports giving strong reasoning on why IPCA Labs is a great buy at the present market rate
ChrysCapital’s recent purchases of big stakes in two mid-cap pharma stocks sends the clear message that Pharma stocks is where the action is at present
Recent Comments